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Abstract
Objective-To assess the effect of inhaled nitric oxide (NO) on severe postoperative pulmonary hypertension in children after surgical repair of a congenital heart defect. Design-A pilot study of NO administration to 7 consecutive children who required adrenergic support and in whom postoperative mean pulmonary artery pressure was more than two thirds of mean systemic pressure and persisted despite alkalotic hyperventilation. Setting-Routine care after cardiac surgery for congenital heart disease in a multidisciplinary paediatric intensive care unit. Methods-Continuous inhalation of NO, initially at 15 ppm. Thereafter, daily attempts at complete weaning or at reducing NO to the lowest effective dose. Results-In 6 of the 7 children NO inhalation selectively decreased mean (SD) pulmonary artery pressure from 51 (12) to 31 (9) mm Hg (P < 0.05) while mean systemic arterial pressure was unchanged (68 (10) v 71 (7) mm Hg) (NS) and the arteriovenous difference in oxygen content decreased from [6] [7] (0.9) to 4-8 (0.8) vol% (P < 0.05). Concomitantly Pao, increased from 158 (98) to 231 (79) mm Hg) (P < 0.05). The seventh child showed no response to NO up to 80 ppm, could not be weaned from cardiopulmonary bypass, and died in the operating room. In responders, attempts at early weaning from NO inhalation always failed and NO at concentrations of less than 10 ppm was continuously administered for a median of fig 1) and showed a tendency to an inverse correlation with the preoperative systemic to pulmonary resistance ratio (A P = -22 Rp/Rs + 26, R2= 0 53, P = 0 07) ( fig  2) . In one patient, who had a thermodilution catheter in place, the pulmonary blood flow increased from 1'5 to 1'8 I/min. In the five other children, the arteriovenous difference in oxygen content-decreased from 6x7 (0'9) to 4, 8 Continuous low dose inhaled nitric oxide for treatment ofsevere pulmonary hypertension after cardiac surgery in paediatnic patients Figure 3 Changes (mean (SEM)) of mean pulmonary artenial pressure ( ) and mean systemic arterial pressure (LO), in six "responders". On the left, inital effect of inhaled NO, on the right, changes seen during the first attempt at weaning offNO and resuming NO at the same concentration on the next day. *P<0-05. 
Discussion
In this pilot study low doses of inhaled NO consistently reduced severe postoperative pulmonary hypertension in children after repair of congenital heart defects. In such patients NO has the advantage of selectively causing pulmonary vasodilation, with a rapid decrease in right ventricular afterload, rather than improving the ventilation perfusion mismatch.
None the less, the rise in Pao, described in patients with diffuse lung injury'2 was also seen. An increase in pulmonary blood flow was measured in one child who had a thermodilution catheter in place and was indicated in the other patients by a significant decrease in the arteriovenous oxygen content difference. Overall haemodynamic improvement was later indicated by the progressive ability to withdraw adrenergic support. All these effects accord with the recent findings of Wessel et al who showed that much of the increase in pulmonary vascular resistance after cardiac surgery is related to endothelial cell dysfunction and that it can be overcome by treatment with NO.2 Additional support for this hypothesis comes from the significant drop in pulmonary pressure that followed NO treatment and correlated positively with the height of postoperative pulmonary artery pressure. This drop tended to correlate negatively with the preoperative pulmonary to systemic vascular resistance ratio. In our patients, these effects were induced by lower concentrations than described previously24 and often, only minute amounts (1 to 4 ppm) were required to maintain low pulmonary artery pressure. Low doses of NO were also effective in lung diseases. " Our selection criteria were defined to apply to children with the most severe postoperative pulmonary hypertension that did not respond to alkalosis-induced pulmonary vasodilation, which has been shown to act independently of the NO pathway. ' hours failed in all these children and resulted in a considerable rise in pulmonary artery pressure within minutes accompanied by a fall in systemic arterial pressure. This meant that during tracheal suctioning a second delivery system had to be used to administer NO. The decision of when and how to attempt weaning is arbitrary. In all cases a tolerable increase in pulmonary artery pressure without systemic haemoglobin desaturation or a drop in systemic pressure was seen only after several days and when the dose of NO had been low. In one case after extubation administration of NO was continued through nasal prongs and was well tolerated. There are two possible explanations why weaning from administration had to be done gradually: (a) a possible down-regulation of the endogenous production of NO once inhalation has been started, '6 and (b) progressive recovery from the cell dysfunction over several days. 2 The dose of inhaled NO that reduced and maintained low pulmonary artery pressure was well below the 25 ppm allowed by the National Institute for Occupational Safety and Health. 17 Concentrations of methaemoglobulin were measured daily and never reached clinically important values. However, the toxicity of NO is mostly associated with its transformation into nitrogen dioxide which can damage the lungs. Low doses of NO and high ventilator flow rates minimises the residence time of the NO/02 mixture in the ventilator circuitry. Nitrogen dioxide concentrations rarely exceeded 0'5 ppm, which is 10 times lower than the upper limit tolerated. '8 The concentrations of 0.1 to 0-2 ppm of nitrogen dioxide that we recorded are commonly detected in the ambient air of many westem industrial cities during the winter. '9 Pulmonary hypertension resolved in six of seven patients given NO. One child later died from an episode of severe anoxia unrelated to his cardiovascular pathology. The five other patients were discharged. All were doing well clinically and showing signs of regression of their pulmonary hypertension at echocardiography or catheterisation several months later.
Low doses of inhaled NO reduced pulmonary hypertension after cardiac surgery in most of these patients. This treatment for a potentially life threatening condition carried little risk of toxicity. This knowledge should help workers to design clinical trials to assess the place of inhaled NO in the complex treatment of pulmonary hypertension after cardiac surgery in children.
